Avalo director granted 1,339 stock options
Avalo Therapeutics director Rita Jain received a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics director Rita Jain received a new stock option grant. On March 31, 2026, she was granted options to acquire 1,339 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The options were granted fully vested and expire on March 31, 2036. Following this grant, she holds 1,339 options directly as reported in this filing.
Insider Trade Summary
Grant/Award: 1,339 shares
Grant/Award
1 txn
Insider
Jain Rita
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 1,339 | $12.13 | $16K |
Holdings After Transaction:
Stock Option (Right to Buy) — 1,339 contracts (Direct)
Footnotes (1)
- F1. The options were granted on March 31, 2026, and are 100% vested.
Key Figures
Options granted: 1,339 options
Exercise price: $14.93 per share
Grant date value reference: $12.13 per option
+2 more
5 metrics
Options granted
1,339 options
Director grant on March 31, 2026
Exercise price
$14.93 per share
Stock option strike price for common stock
Grant date value reference
$12.13 per option
Reported transaction price per option at grant
Total options held after grant
1,339 options
Total derivative holdings following this transaction
Option expiration
March 31, 2036
Expiration date of granted stock options
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, derivative
4 terms
Stock Option (Right to Buy) financial
"Security title listed as "Stock Option (Right to Buy)" for the grant."
Grant, award, or other acquisition financial
"Transaction code description states "Grant, award, or other acquisition"."
Common Stock financial
"Underlying security title for the option is shown as "Common Stock"."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
derivative financial
"Transaction type is categorized as "derivative" in the data."
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Avalo Therapeutics (AVTX) report for Rita Jain?
Avalo Therapeutics (AVTX) reported that director Rita Jain received a grant of 1,339 stock options on March 31, 2026. These options give her the right to buy common shares at a preset price as part of her compensation package.
What is the exercise price of Rita Jain’s new AVTX stock options?
The granted options allow director Rita Jain to buy Avalo Therapeutics (AVTX) common stock at an exercise price of $14.93 per share. This strike price is fixed for the life of the option, regardless of future market price movements.
How many Avalo Therapeutics (AVTX) options does Rita Jain hold after this filing?
After the reported grant, director Rita Jain holds 1,339 stock options in Avalo Therapeutics (AVTX). The filing shows this full amount as her direct derivative holdings following the transaction, reflecting only this single option award.
When do Rita Jain’s Avalo Therapeutics (AVTX) stock options expire?
The stock options granted to director Rita Jain in Avalo Therapeutics (AVTX) expire on March 31, 2036. She can choose to exercise them any time before this expiration date, subject to the option terms and her own decisions.
Are Rita Jain’s new AVTX stock options already vested?
Yes. The footnote explains that Rita Jain’s Avalo Therapeutics (AVTX) options granted on March 31, 2026 are 100% vested. This means she has the immediate right to exercise them, rather than waiting for a vesting schedule to complete.
AI-generated analysis. How Rhea-AI works. Not financial advice.
